Skip to content
Biotech Intelligence

Zhejiang Wenda Pharma Technology LTD.

biotechChina
Trials
0
Subs
0
People
0
Links
0

Executive Summary

AI synthesis

Zhejiang Wenda Pharma Technology LTD is a Chinese biotech company with limited publicly available information, which presents significant due diligence challenges for potential US partners. The company has clear BIOSECURE status, suggesting no current designation as a threat entity. However, the lack of disclosed key personnel, subsidiaries, or recent corporate events indicates either early-stage operations or limited transparency that warrants cautious evaluation.

Structure: Corporate structure details are not available from public sources, making it impossible to determine if the company operates through VIE structures or complex holding company arrangements typical of Chinese biotechs. This opacity in corporate structure should be a priority area for due diligence inquiry.

BIOSECURE Risk

medium

While currently showing 'clear' BIOSECURE status, the lack of transparency and limited public information creates uncertainty about future designation risk

Key Exposures:

  • •Limited public disclosure creating due diligence gaps
  • •Potential undisclosed government relationships
  • •Unclear corporate structure

Mitigation: No evidence of proactive BIOSECURE compliance measures or structural modifications

BD Intelligence

Pipeline Strength3/10
Deal Readiness2/10

Therapeutic Areas:

Unknown - insufficient data

Recent Deals: No recent deal activity identified

Approach: Proceed with extreme caution and comprehensive due diligence; request detailed corporate structure, pipeline assets, and key personnel information before any substantive discussions

Red Flags

  • ⚠Complete lack of publicly available key personnel information
  • ⚠No disclosed subsidiary structure
  • ⚠Absence of recent corporate events or milestones
  • ⚠Limited transparency typical for credible biotech operations
  • ⚠Insufficient information to conduct proper due diligence

Quick Facts

Key People
0
Subsidiaries
0
CDMO/CRO Subs
0
Genomics Subs
0
Direct BIOSECURE
0
Corp Events
0
Gov-Connected
0
Clinical Trials
0
Publications
0
Drug Molecules
0
Relationships
0

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (0 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.